Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Pivotal Phase 2 Trial of Antibody Naxitamab (hu3F8) and Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) in High-Risk Neuroblastoma Patients With Primary Refractory Disease or Incomplete Response to Salvage Treatment in Bone and/or Bone Marrow

NCT03363373 is registered in ClinicalTrials.gov with Y-mAbs Therapeutics as lead sponsor.

NCT NCT03363373
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03363373 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Pivotal Phase 2 Trial of Antibody Naxitamab (hu3F8) and Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) in High-Risk Neuroblastoma Patients With Primary Refractory Disease or Incomplete Response to Salvage Treatment in Bone and/or Bone Marrow
Lead sponsor
Y-mAbs Therapeutics
Phase
Phase 2
Overall status
Active, not recruiting
Start date
April 3, 2018
Completion date
April 30, 2028
Enrollment
122 (estimated)
Sites
20

Conditions

As the registry lists them; a condition with its own page is linked.

neuroblastoma